Guoji laonian yixue zazhi (Nov 2024)
The Application of Hydromorphone Combined with Low-dose Promethazine in Elderly Patients with End-stage Cancer Pain
Abstract
Objective To investigate the application and safety analysis of low-dose promethazine combined with hydromorphone in elderly patients with end-stage cancer pain. Methods A total of 58 elderly patients with end-stage cancer pain admitted to Jilin Province People’s Hospital from April 2022 to December 2022 were selected for prospective study, they were randomly divided into an experimental group (30 cases) and a control group (28 cases) according to random number table method. The experimental group received low-dose promethazine combined with hydromorphone for analgesic treatment, and the control group received single drug hydromorphone for analgesic treatment. The cancer pain［numeric rating scale (NRS)］, daily dose of hydromorphone, sleep quality assessment ［pittsburgh sleep quality index (PSQI)］, mental status assessment ［Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA)］ and adverse reactions were compared between the two groups. Results The RNS scores of the two groups decreased after treatment compared with those before treatment (P<0.05), and the experimental group was lower than the control group (P<0.05). On the 7th day of treatment, daily dose of hydromorphone,the PSQI score, HAMD and HAMA scores in the test group were lower than those before treatment (P<0.05), and the scores in the experimental group were lower than those in the control group (P<0.05). The incidence of constipation, nausea and vomiting in the experimental group was lower than that in the control group (P<0.05), and the incidence of somnolence was higher than that in the control group (P<0.05). Conclusion Hydromorphone combined with low-dose promethazine can alleviate intractable cancer pain in elderly patients with end-stage cancer, and demonstrate tolerable adverse reactions. Therefore, it is worthy of clinical promotion.
Keywords
